WPRIM Management System> DCMS> Chinese Journal of Cancer> 2015> 34> 7

Volume: 34 Issue: 7

1. Global efforts in conquering lung cancer in China. Page:320—322
2. Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough. Page:310—319
3. Insight into early-phase trials for lung cancer in the United States. Page:288—294
4. Early-Phase Oncology Research Training (EFFORT) program: a Hengrui-USCACA joint scholarship. Page:323—324
5. Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance. Page:285—287
6. Predictive biomarkers in precision medicine and drug development against lung cancer. Page:295—309

©2019 - Present World Health Organization Regional Office for the Western Pacific. All Rights Reserved.